UK Markets closed

Chugai Pharmaceutical Co., Ltd. (CHGCF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
26.460.00 (0.00%)
At close: 09:30AM EST

Chugai Pharmaceutical Co., Ltd.

Nihonbashi Mitsui Tower
15th Floor 1-1 Nihonbashi-Muromachi 2-chome Chuo-ku
Tokyo 103-8324
81 3 3281 6611

IndustryDrug Manufacturers—General
Full-time employees7,664

Key executives

NameTitlePayExercisedYear born
Dr. Osamu OkudaPres, CEO & Representative Director449.9kN/A1963
Mr. Toshiaki ItagakiHead of Fin. Supervisory Division, CFO, Exec. VP & DirectorN/AN/A1960
Toshiya SasaiExec. of Investor Relations Group & Corp. Communications DepartmentN/AN/AN/A
Masahiko UchidaGen. Mang. of Corp. Communications DepartmentN/AN/AN/A
Mr. Shinji HidakaExec. VP and Head of Marketing & Sales DivisionN/AN/AN/A
Mr. Tsunanori SatoVP and GM of Marketing & Sales DivisionN/AN/AN/A
Mr. Yoshiyuki YanoExec. VP & Head of HR Management DepartmentN/AN/AN/A
Mr. Junichi EbiharaExec. VPN/AN/AN/A
Dr. Yoshiaki OhashiSVP & Full-time Audit Supervisory Board MemberN/AN/A1960
Mr. Tetsuya YamaguchiExec. VP and Head of Project & Lifecycle Management UnitN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

Corporate governance

Chugai Pharmaceutical Co., Ltd.’s ISS governance QualityScore as of 1 October 2022 is 5. The pillar scores are Audit: 1; Board: 6; Shareholder rights: 8; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.